Evidence map›Paper›PMID 36001375›Full record

ArticleMolecular biology of the cell2022

Noncanonical Wnt/Ror2 signaling regulates cell-matrix adhesion to prompt directional tumor cell invasion in breast cancer.

Hongjiang Si, Na Zhao, Andrea Pedroza, Ana-Maria Zaske, Jeffrey M Rosen, Chad J Creighton, Kevin Roarty

Open access · greenAbstract read
In one paragraph

Article in Molecular biology of the cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hongjiang SiDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030.
Na ZhaoDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030.
Andrea PedrozaDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030.
Ana-Maria ZaskeUniversity of Texas Health Science Center at Houston, Houston, TX 77054.
Jeffrey M RosenDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030.
Chad J CreightonBreast Cancer Program, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030.
Kevin RoartyDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030.ORCID 0000-0002-3307-0609
Baylor College of Medicine · USThe University of Texas Health Science Center at Houston · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9M
Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Hashem B El-Serag · 2001 to 2026
$28.3M
Translational Research in Breast Cancer (SPORE)P50CA186784 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MATTHEW J ELLIS · 2014 to 2026
$24.5M
Translational Research Support CoreP30ES030285 · NIEHS · BAYLOR COLLEGE OF MEDICINE · PI Cheryl L. Walker · 2019 to 2026
$14.7M
MALAT1 lncRNA as a Therapeutic Target in Triple Negative Breast CancerR01CA016303 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ROSEN, JEFFREY MARK · 1985 to 2022
$8.1M
HORMONAL REGULATION OF BREAST CANCERR37CA016303 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ROSEN, JEFFREY MARK · 1989 to 2011
$7.3M
Therapeutic Targeting of Breast Cancer Tumor Initiating CellsR01CA148761 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, ROSEN, JEFFREY MARK · 2010 to 2025
$6.5M
Wnt pathway dynamics in breast cancer metastasisK22CA207463 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ROARTY, KEVIN P. · 2017 to 2019
$564k
BD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430k
NCI NIH HHS K22 CA207463NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA186784NCI NIH HHS R01 CA016303NCI NIH HHS R01 CA148761NCI NIH HHS R37 CA016303NCRR NIH HHS S10 RR024574NIDDK NIH HHS P30 DK056338NIEHS NIH HHS P30 ES030285
6 · The paper itself

Abstract

Cell-extracellular matrix (ECM) interactions represent fundamental exchanges during tumor progression, yet how particular signal-transduction factors prompt the conversion of tumor cells into migratory populations capable of systemic spread during metastasis remains elusive. We demonstrate that the noncanonical Wnt receptor, Ror2, regulates tumor cell-driven matrix remodeling and invasion in breast cancer. Ror2 loss-of-function (LOF) triggers the disruption of E-cadherin within tumor cells, accompanied by an increase in tumor cell invasion and collagen realignment in three-dimensional cultures. RNA sequencing of Ror2-deficient organoids further uncovered alterations in actin cytoskeleton, cell adhesion, and collagen cross-linking gene expression programs. Spatially, we pinpoint the up-regulation and redistribution of α

Indexed as

Breast NeoplasmsCell AdhesionCell Line, TumorCell-Matrix JunctionsFemaleHumansIntegrinsReceptor Tyrosine Kinase-like Orphan ReceptorsWnt Signaling PathwayIntegrinsReceptor Tyrosine Kinase-like Orphan ReceptorsROR2 protein, human

Identifiers

PMID36001375
PMCPMC9582800
OpenAlexW4292940468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.